IPHA (Innate Pharma S.A.) Rasio Nilai Pasar marang Nilai Buku

Innate Pharma S.A. (IPHA) leverages the expertise of French immunologists who value academic freedom and prestige within the biotech sector. High trust from the global community has cemented the brand's status as an authoritative drug developer. The market dynamics reflected in the price action captured the -2.99 metric. Innate Pharma S.A. (IPHA) leads the development of NK-cell therapies, utilizing the ANKET system to create antibodies that gently activate the body's defenses against tumors.

Innate Pharma S.A (IPHA): Rasio Kapitalisasi marang Nilai Buku saka 04.07.2022 nganti 27.10.2026

Rincian metrik keuangan lan pasar Innate Pharma SA (IPHA)

- rega lan prakiraan konsensus rega:

Rega saham Innate Pharma S.A.|IPHA - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Innate Pharma, S.A.|IPHA - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Innate Pharma|IPHA - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku innate-pharma.com|IPHA - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Innate Pharma S.A.|IPHA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Innate Pharma, S.A.|IPHA - Utang perusahaan|Rasio utang marang kapitalisasi buku Innate Pharma, S.A.

Pambiji fundamental:Innate Pharma S.A.

This indicator determines the proportionality of the market value of Innate Pharma S.A. (IPHA) to its net book value, reflecting the premium or discount to real capital through the ratio of share prices to balance sheet data. Analyzing the ratio of the company's market capitalization to its book capitalization allows for an assessment of the value of its intellectual property, including the unique ANKET platform and long-term licensing agreements with global pharma behemoths.

Analisis pesaing